Abdalla Aly1, Ruchitbhai Shah1, Kala Hill2, Marc F Botteman1. 1. Pharmerit International, 4350 East-West Hwy, Suite 1110, Bethesda, MD 20814, USA. 2. Celldex Therapeutics, 53 I-78 Frontage Rd, Hampton, NJ 08827, USA.
Abstract
AIM: This analysis estimated the overall survival, treatment patterns and economic burden of elderly metastatic triple-negative breast cancer patients. MATERIALS & METHODS: Patients (≥66 years) with metastatic triple-negative breast cancer were identified from the SEER-Medicare database. Treatment patterns were defined in terms of first, second and third or more regimens. Healthcare resource use and costs were reported over the follow-up period and over the treatment duration of each regimen. RESULTS: A total of 51% of patients did not receive chemotherapy. Taxanes were most commonly used. Median survival was 7 months. The mean cumulative (per patient per month) cost per patient was US$73,586 (US$10,084). Mean cost in first and second regimen were US$26,950 and US$33,347. CONCLUSION: About half of patients did not receive chemotherapy. Receipt of increasing regimens led to higher mean costs and healthcare resource use.
AIM: This analysis estimated the overall survival, treatment patterns and economic burden of elderly metastatic triple-negative breast cancerpatients. MATERIALS & METHODS:Patients (≥66 years) with metastatic triple-negative breast cancer were identified from the SEER-Medicare database. Treatment patterns were defined in terms of first, second and third or more regimens. Healthcare resource use and costs were reported over the follow-up period and over the treatment duration of each regimen. RESULTS: A total of 51% of patients did not receive chemotherapy. Taxanes were most commonly used. Median survival was 7 months. The mean cumulative (per patient per month) cost per patient was US$73,586 (US$10,084). Mean cost in first and second regimen were US$26,950 and US$33,347. CONCLUSION: About half of patients did not receive chemotherapy. Receipt of increasing regimens led to higher mean costs and healthcare resource use.
Entities:
Keywords:
SEER-Medicare; chemotherapy; elderly; metastatic disease; triple-negative breast cancer
Authors: Nagavarakishore Pillarsetty; Komal Jhaveri; Tony Taldone; Eloisi Caldas-Lopes; Blesida Punzalan; Suhasini Joshi; Alexander Bolaender; Mohammad M Uddin; Anna Rodina; Pengrong Yan; Anson Ku; Thomas Ku; Smit K Shah; Serge Lyashchenko; Eva Burnazi; Tai Wang; Nicolas Lecomte; Yelena Janjigian; Anas Younes; Connie W Batlevi; Monica L Guzman; Gail J Roboz; Jacek Koziorowski; Pat Zanzonico; Mary L Alpaugh; Adriana Corben; Shanu Modi; Larry Norton; Steven M Larson; Jason S Lewis; Gabriela Chiosis; John F Gerecitano; Mark P S Dunphy Journal: Cancer Cell Date: 2019-10-24 Impact factor: 31.743
Authors: Min Huang; Amin Haiderali; Grace E Fox; Andrew Frederickson; Javier Cortes; Peter A Fasching; Joyce O'Shaughnessy Journal: Pharmacoeconomics Date: 2022-02-03 Impact factor: 4.558